Molecular Templates (NASDAQ:MTEM) issued its earnings results on Monday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.02), Fidelity Earnings reports. Molecular Templates had a negative return on equity of 26.91% and a negative net margin of 113.85%. The firm had revenue of $5.45 million during the quarter, compared to analysts’ expectations of $6.00 million.
Shares of MTEM stock opened at $4.60 on Thursday. The company has a 50-day moving average price of $6.96. The company has a quick ratio of 3.24, a current ratio of 3.24 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $184.21 million, a price-to-earnings ratio of -4.51 and a beta of 2.77. Molecular Templates has a fifty-two week low of $3.19 and a fifty-two week high of $8.77.
MTEM has been the subject of a number of analyst reports. TheStreet cut Molecular Templates from a “c-” rating to a “d” rating in a research note on Monday, August 5th. BidaskClub cut Molecular Templates from a “hold” rating to a “sell” rating in a research note on Friday, July 26th. Cowen restated a “buy” rating on shares of Molecular Templates in a research note on Tuesday. Zacks Investment Research cut Molecular Templates from a “buy” rating to a “hold” rating in a research note on Wednesday, June 5th. Finally, ValuEngine lowered Molecular Templates from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Molecular Templates presently has an average rating of “Buy” and an average target price of $13.58.
About Molecular Templates
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma.
Featured Story: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.